TY  - JOUR
T1  - Study halted: No benefit seen from antiretroviral pill in preventing hiv in women
AU  - Stephenson J
Y1  - 2011/05/18
N1  - 10.1001/jama.2011.649
JO  - JAMA
SP  - 1952
EP  - 1952
VL  - 305
IS  - 19
N2  - 
The study, called FEM-PrEP, is a randomized clinical trial of the safety and effectiveness of a daily pill containing emtricitabine and tenofovir (a combination sold under the name Truvada) in preventing HIV infection in women in Africa who are at higher risk of being exposed to HIV. It is one of several trials testing the use of antiretroviral drugs as a prevention strategy in at-risk populations.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2011.649
UR  - http://dx.doi.org/10.1001/jama.2011.649
ER  -